Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011439 · ClinicalTrials.gov registry record · Phase 2
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma
A Phase 2 study, sponsored by Tiziana Life Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01011439: Clinical Trial Phase 2 study, sponsored by Tiziana Life Sciences.
NCT01011439 is a Phase 2 study that was terminated before completion, run by Tiziana Life Sciences. The registered enrollment target is 72 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011439, a Phase 2 study, was terminated before completion, sponsored by Tiziana Life Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.
Primary Outcome
The proportion of successes (i.e. patients alive and progression free at 3 months since treatment start) out of the total number of evaluable patients
Interventions
- DRUG Milciclib Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2010-02-22 |
| Est. Completion | 2018-12-17 |
| Phase | Phase 2 |
Why NCT01011439 stopped before completion
NCT01011439 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (46% lower).
The record links to 0 conditions, and to 1 intervention - of which Milciclib Maleate is the first listed.
NCT01011439 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01011439 about?
NCT01011439 is a clinical study titled "Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma". The intent of the study is to assess the antitumor activity of PHA-848125AC as second-line treatment in patients with recurrent or metastatic, unresectable thymic carcinoma previously treated with chemotherapy.
What is the current status of trial NCT01011439?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2010-02-22. Estimated completion is 2018-12-17.
What interventions are being tested in trial NCT01011439?
The interventions under investigation include: Milciclib Maleate (DRUG).
Who is sponsoring clinical trial NCT01011439?
This trial is sponsored by Tiziana Life Sciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01011439's enrollment target sits among peer trials
72 925th of 2000 higher than 1,065 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI